Cardiac arrest & resuscitation
Modulation of inflammation by treatment with tocilizumab after out-of-hospital cardiac arrest and associations with clinical status, myocardial- and brain injury
Authors' conclusion
Treatment with tocilizumab after OHCA modulated the inflammatory response with notable increases for IL-5, IL-6, and decreases for neutrophils and monocytes, as well as reduced vasopressor and inotropy requirements.
Study context
- Population
- Comatose out-of-hospital cardiac arrest (OHCA) patients
- Participants
- 80 patients
- Comparison
- Tocilizumab vs placebo
Methodological detailspreplanned substudy
- Preplanned substudy
Primary result
As reported in the abstract
Inflammatory response, myocardial and brain injury markers, clinical status
- Responses for IL-5, IL-6, IL-17, neutrophil and monocyte counts and Vasoactive-Inotropic Score (VIS) affected by tocilizumab
- all p < 0.05
Further findings
Correlations of organ injury and clinical status markers with inflammatory markers
- Neutrophils and monocytes correlated with TnT, neuron-specific enolase (NSE), NFL, SOFA and VIS in Tocilizumab but not Placebo
- NT-proBNP, NFL and SOFA correlated with CRP in both groups
Original publication
Modulation of inflammation by treatment with tocilizumab after out-of-hospital cardiac arrest and associations with clinical status, myocardial- and brain injury. Resuscitation. Published 24 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →